We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Pointe Scientific

Pointe Scientific Inc. develops, manufactures, and distributes over 400 clinical diagnostic products. The company’s p... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Testosterone Reference Ranges Vary Widely in Medical Laboratories

By LabMedica International staff writers
Posted on 30 Jun 2016
Print article
Image: The enzyme immunoassay for quantitative determination of testosterone concentration in human serum (Photo courtesy of Pointe Scientific).
Image: The enzyme immunoassay for quantitative determination of testosterone concentration in human serum (Photo courtesy of Pointe Scientific).
The evaluation and management of male hypogonadism should be based on symptoms and on serum testosterone levels and diagnostically this relies on accurate testing and reference values. This circumstance not only affects how clinicians determine treatment, but also whether insurers approve therapy for men with low testosterone levels.

Numerous variables affect testosterone level results, including the patient’s age and weight, physiological variation, timing of the specimen draw, presence of comorbid conditions, and medications, all of which makes defining a clinically relevant lower limit of “normal” challenging. In particular, as levels approach hypogonadal states, the accuracy becomes increasingly unreliable.

Urologists at the University of Kansas Medical Center (Kansas City, KS, USA) surveyed 120 academic and community hospital-associated laboratories in 47 states, 73% of which measured total testosterone on site using radioimmunoassay (RIA), enzyme immunoassay (EIA), and/or liquid chromatography-tandem mass spectrometry. Most (94.3%) used EIA via high-throughput analyzers.

The scientists found that total testosterone was measured in house at 73% of laboratories. At the remaining laboratories studies were sent to larger centralized reference facilities. The mean ± SD lower reference value of total testosterone was 231 ± 46 ng/dL (range 160 to 300) and the mean upper limit was 850 ± 141 ng/dL (range 726 to 1,130). Only 9% of laboratories where in-house total testosterone testing was performed created a reference range unique to their region. Others validated the instrument recommended reference values in a small number of internal test samples. For free testosterone 82% of laboratories sent testing to larger centralized reference laboratories where equilibrium dialysis and/or liquid chromatography with mass spectrometry was done. The remaining laboratories used published algorithms to calculate serum free testosterone.

The authors concluded that reference ranges for testosterone assays vary significantly among laboratories. The ranges are predominantly defined by limited population studies of men with unknown medical and reproductive histories. These poorly defined and variable reference values, especially the lower limit, affect how clinicians determine treatment. The study was published in the May 2016 issue of the Journal of Urology.

Related Links:
University of Kansas Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.